GlobalData Release: Rapid Heart Rates Grow Faster as Drug Treatments Threaten Lives

Published: Jul 26, 2012

LONDON, UK (GlobalData), 26 July 2012 - Major safety fears over supraventricular tachycardia (SVT) medications are threatening many elderly patients, and even encouraging some to opt for surgery, claims a new report by healthcare experts GlobalData.

The new report* shows that the prognosis for SVT is good if there are no associated co-morbidities, but with time, more frequent and long-lasting episodes are seen in almost all patients, who are forced to adhere to treatments potentially even more dangerous to their health than the condition itself.

However, some set-backs in the SVT therapeutics market may have a negative impact on patient wellbeing. Negative opinions of antiarrhythmic Multaq have emerged among physicians following the black box warning given by the US FDA on December 19, 2011, noting that the drug must be not prescribed for people with a history of heart failure. Multaq was found to double the risk of death in patients with symptomatic heart failure and New York Heart Association (NYHA) Class IV heart failure, three months after the launch of Multaq in Europe. The European Medicines Agency (EMA) also advised that Multaq must only be used as a last resort. These negative opinions will affect the market share of products.

Another antiarrhythmic drug, Brinavess, was filed in the US in 2007, but has still not received approval due to a patient suffering cardiogenic shock in a pivotal trial. Even if the drug is approved, the resulting negative perception of the product may affect its future market share. Amiodarone, another antiarrhythmic, gained a negative opinion due to adverse events related to toxicity in the brain, kidney, liver and other organs, as well as an overestimation of bleeding risk, and the underestimation of stroke risk associated with anticoagulants. All of these issues discourage physicians from prescribing such drugs.

Patients can be given adenosine (Adenocard), which is a fast-acting intravenous (IV) antiarrhythmic agent that can offer faster activation if given by IV. Adenosine treatment is highly efficacious, yet it still has uncomfortable temporary side effects, including chest pain, flushing, nausea, breathlessness, and dizziness.

SVT patients also suffer a high risk of strokes due to embolism, which can be prevented by anticoagulants such as warfarin, and the recently approved Xarelto and Pradaxa. However, the low safety profiles of such drugs due to bleeding complications mean that the prescription rate of these drugs is low.

As a result, ablation is the treatment of choice for many cardiologists. Procedures such as radiofrequency ablation have increased preference in recent years for the treatment of SVT, and boast more than 85% success rate with few complications. Due to the various risks of drug treatments, more and more cardiologists prefer procedures over medication. Other treatments can also include pacemakers, or cardioversion (an electric shock) to restore the heart’s normal rhythm.

*Supraventricular Tachycardia (SVT) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 This report is an essential source of information and analysis on the global Supraventricular Tachycardia (SVT) therapeutics market. It identifies the key trends shaping and driving the global market, and provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global SVT therapeutics sector.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.


GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For more information, please contact our Press Office on +44 (0)1204 543 537 or at

Back to news